ID   PAK1_HUMAN              Reviewed;         545 AA.
AC   Q13153; O75561; Q13567; Q32M53; Q32M54; Q86W79;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 2.
DT   05-OCT-2010, entry version 123.
DE   RecName: Full=Serine/threonine-protein kinase PAK 1;
DE            EC=2.7.11.1;
DE   AltName: Full=Alpha-PAK;
DE   AltName: Full=p21-activated kinase 1;
DE            Short=PAK-1;
DE   AltName: Full=p65-PAK;
GN   Name=PAK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   MEDLINE=96398842; PubMed=8805275; DOI=10.1016/S0960-9822(02)00546-8;
RA   Brown J.L., Stowers L., Baer M., Trejo J., Coughlin S., Chant J.;
RT   "Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase
RT   pathway.";
RL   Curr. Biol. 6:598-605(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=97199447; PubMed=9395435; DOI=10.1016/S0960-9822(97)70091-5;
RA   Sells M.A., Knaus U.G., Bagrodia S., Ambrose D.M., Bokoch G.M.,
RA   Chernoff J.;
RT   "Human p21-activated kinase (Pak1) regulates actin organization in
RT   mammalian cells.";
RL   Curr. Biol. 7:202-210(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Reid T., Aspenstroem P., Bertoglio J.;
RT   "Human PAK1B.";
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   ENZYME REGULATION, AND SUBCELLULAR LOCATION.
RX   PubMed=9032240;
RA   Manser E., Huang H.Y., Loo T.H., Chen X.Q., Dong J.M., Leung T.,
RA   Lim L.;
RT   "Expression of constitutively active alpha-PAK reveals effects of the
RT   kinase on actin and focal complexes.";
RL   Mol. Cell. Biol. 17:1129-1143(1997).
RN   [6]
RP   MUTAGENESIS OF HIS-83 AND HIS-86.
RX   PubMed=9774440; DOI=10.1074/jbc.273.43.28191;
RA   Frost J.A., Khokhlatchev A., Stippec S., White M.A., Cobb M.H.;
RT   "Differential effects of PAK1-activating mutations reveal activity-
RT   dependent and -independent effects on cytoskeletal regulation.";
RL   J. Biol. Chem. 273:28191-28198(1998).
RN   [7]
RP   FUNCTION, AND AUTOREGULATORY DOMAIN.
RX   PubMed=9528787;
RA   Zhao Z.S., Manser E., Chen X.Q., Chong C., Leung T., Lim L.;
RT   "A conserved negative regulatory region in alphaPAK: inhibition of PAK
RT   kinases reveals their morphological roles downstream of Cdc42 and
RT   Rac1.";
RL   Mol. Cell. Biol. 18:2153-2163(1998).
RN   [8]
RP   PHOSPHORYLATION AT THR-423, AND MUTAGENESIS OF THR-423.
RX   PubMed=10551809; DOI=10.1074/jbc.274.46.32565;
RA   Zenke F.T., King C.C., Bohl B.P., Bokoch G.M.;
RT   "Identification of a central phosphorylation site in p21-activated
RT   kinase regulating autoinhibition and kinase activity.";
RL   J. Biol. Chem. 274:32565-32573(1999).
RN   [9]
RP   DIMERIZATION, AND ENZYME REGULATION.
RX   PubMed=11804587; DOI=10.1016/S1097-2765(01)00428-2;
RA   Parrini M.C., Lei M., Harrison S.C., Mayer B.J.;
RT   "Pak1 kinase homodimers are autoinhibited in trans and dissociated
RT   upon activation by Cdc42 and Rac1.";
RL   Mol. Cell 9:73-83(2002).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH CDC2L1 AND CDC2L2.
RX   MEDLINE=22651041; PubMed=12624090; DOI=10.1074/jbc.M300818200;
RA   Chen S., Yin X., Zhu X., Yan J., Ji S., Chen C., Cai M., Zhang S.,
RA   Zong H., Hu Y., Yuan Z., Shen Z., Gu J.;
RT   "The C-terminal kinase domain of the p34cdc2-related PITSLRE protein
RT   kinase (p110C) associates with p21-activated kinase 1 and inhibits its
RT   activity during anoikis.";
RL   J. Biol. Chem. 278:20029-20036(2003).
RN   [11]
RP   INTERACTION WITH DSCAM.
RX   PubMed=15169762; DOI=10.1074/jbc.M401878200;
RA   Li W., Guan K.L.;
RT   "The Down syndrome cell adhesion molecule (DSCAM) interacts with and
RT   activates Pak.";
RL   J. Biol. Chem. 279:32824-32831(2004).
RN   [12]
RP   FUNCTION.
RX   PubMed=15831477; DOI=10.1128/MCB.25.9.3726-3736.2005;
RA   Vadlamudi R.K., Barnes C.J., Rayala S., Li F., Balasenthil S.,
RA   Marcus S., Goodson H.V., Sahin A.A., Kumar R.;
RT   "p21-activated kinase 1 regulates microtubule dynamics by
RT   phosphorylating tubulin cofactor B.";
RL   Mol. Cell. Biol. 25:3726-3736(2005).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-212, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH CRIPAK.
RX   PubMed=16278681; DOI=10.1038/sj.onc.1209172;
RA   Talukder A.H., Meng Q., Kumar R.;
RT   "CRIPak, a novel endogenous Pak1 inhibitor.";
RL   Oncogene 25:1311-1319(2006).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-230, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [17]
RP   INTERACTION WITH SCRIB.
RX   PubMed=18716323; DOI=10.1093/hmg/ddn248;
RA   Nola S., Sebbagh M., Marchetto S., Osmani N., Nourry C., Audebert S.,
RA   Navarro C., Rachel R., Montcouquiol M., Sans N.,
RA   Etienne-Manneville S., Borg J.-P., Santoni M.-J.;
RT   "Scrib regulates PAK activity during the cell migration process.";
RL   Hum. Mol. Genet. 17:3552-3565(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-212; THR-225; THR-229
RP   AND THR-230, AND MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-474, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=19534553; DOI=10.1021/pr900044c;
RA   Heibeck T.H., Ding S.-J., Opresko L.K., Zhao R., Schepmoes A.A.,
RA   Yang F., Tolmachev A.V., Monroe M.E., Camp D.G. II, Smith R.D.,
RA   Wiley H.S., Qian W.-J.;
RT   "An extensive survey of tyrosine phosphorylation revealing new sites
RT   in human mammary epithelial cells.";
RL   J. Proteome Res. 8:3852-3861(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-144; SER-204; THR-212;
RP   THR-219; SER-220 AND THR-230, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-256, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 70-545.
RX   PubMed=10975528; DOI=10.1016/S0092-8674(00)00043-X;
RA   Lei M., Lu W., Meng W., Parrini M.C., Eck M.J., Mayer B.J.,
RA   Harrison S.C.;
RT   "Structure of PAK1 in an autoinhibited conformation reveals a
RT   multistage activation switch.";
RL   Cell 102:387-397(2000).
RN   [23]
RP   STRUCTURE BY NMR OF 183-204 IN COMPLEX WITH ARHGEF7.
RX   PubMed=16101281; DOI=10.1021/bi050374a;
RA   Mott H.R., Nietlispach D., Evetts K.A., Owen D.;
RT   "Structural analysis of the SH3 domain of beta-PIX and its interaction
RT   with alpha-p21 activated kinase (PAK).";
RL   Biochemistry 44:10977-10983(2005).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 249-545, AND ENZYME
RP   REGULATION.
RX   PubMed=15893667; DOI=10.1016/j.str.2005.03.007;
RA   Lei M., Robinson M.A., Harrison S.C.;
RT   "The active conformation of the PAK1 kinase domain.";
RL   Structure 13:769-778(2005).
CC   -!- FUNCTION: The activated kinase acts on a variety of targets.
CC       Likely to be the GTPase effector that links the Rho-related
CC       GTPases to the JNK MAP kinase pathway. Activated by CDC42 and
CC       RAC1. Involved in dissolution of stress fibers and reorganization
CC       of focal complexes. Involved in regulation of microtubule
CC       biogenesis through phosphorylation of TBCB. Activity is inhibited
CC       in cells undergoing apoptosis, potentially due to binding of
CC       CDC2L1 and CDC2L2.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Magnesium.
CC   -!- ENZYME REGULATION: Activated by binding small G proteins. Binding
CC       of GTP-bound CDC42 or RAC1 to the autoregulatory region releases
CC       monomers from the autoinhibited dimer, enables phosphorylation of
CC       Thr-423 and allows the kinase domain to adopt an active structure.
CC       Also activated by binding to GTP-bound CDC42, independent of the
CC       phosphorylation state of Thr-423. Phosphorylation of Thr-84 by
CC       OXSR1 inhibits this activation (By similarity).
CC   -!- SUBUNIT: Homodimer in its autoinhibited state. Active as monomer.
CC       Interacts tightly with GTP-bound but not GDP-bound CDC42/P21 and
CC       RAC1. Binds to the caspase-cleaved p110 isoform of CDC2L1 and
CC       CDC2L2, p110C, but not the full-length proteins. Component of
CC       cytoplasmic complexes, which also contain PXN, ARHGEF6 and GIT1.
CC       Interacts with ARHGEF7. Also interacts with CRIPAK. Interacts with
CC       NISCH (By similarity). Probably found in a ternary complex
CC       composed of DSCAM, PAK1 and RAC1. Interacts with DSCAM (via
CC       cytoplasmic domain); the interaction is direct and enhanced in
CC       presence of RAC1. Interacts with SCRIB.
CC   -!- INTERACTION:
CC       P60953:CDC42; NbExp=2; IntAct=EBI-1307, EBI-81752;
CC       P60766:Cdc42 (xeno); NbExp=1; IntAct=EBI-1307, EBI-81763;
CC       P21127:CDK11B; NbExp=2; IntAct=EBI-1307, EBI-1298;
CC       Q8N1N5:CRIPAK; NbExp=5; IntAct=EBI-1307, EBI-1205846;
CC       P63000:RAC1; NbExp=4; IntAct=EBI-1307, EBI-413628;
CC       P63001:Rac1 (xeno); NbExp=1; IntAct=EBI-1307, EBI-413646;
CC       Q7L0Q8:RHOU; NbExp=2; IntAct=EBI-1307, EBI-1638043;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell junction, focal adhesion.
CC       Note=Recruited to focal adhesions upon activation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13153-1; Sequence=Displayed;
CC       Name=2; Synonyms=PAK1B;
CC         IsoId=Q13153-2; Sequence=VSP_017507;
CC   -!- PTM: Autophosphorylated when activated by CDC42/p21 and RAC1.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily.
CC   -!- SIMILARITY: Contains 1 CRIB domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PAK1ID41633ch11q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U51120; AAC50590.1; -; mRNA.
DR   EMBL; U24152; AAA65441.1; -; mRNA.
DR   EMBL; AF071884; AAC24716.1; -; mRNA.
DR   EMBL; BC109299; AAI09300.1; -; mRNA.
DR   IPI; IPI00289746; -.
DR   IPI; IPI00656138; -.
DR   PIR; G01773; G01773.
DR   RefSeq; NP_001122092.1; -.
DR   RefSeq; NP_002567.3; -.
DR   UniGene; Hs.435714; -.
DR   PDB; 1F3M; X-ray; 2.30 A; A/B=70-149, C/D=249-545.
DR   PDB; 1YHV; X-ray; 1.80 A; A=249-545.
DR   PDB; 1YHW; X-ray; 1.80 A; A=249-545.
DR   PDB; 1ZSG; NMR; -; B=183-204.
DR   PDB; 2HY8; X-ray; 2.00 A; 1=249-545.
DR   PDB; 2QME; X-ray; 1.75 A; I=74-109.
DR   PDB; 3DVP; X-ray; 2.50 A; C/D=212-221.
DR   PDB; 3FXZ; X-ray; 1.64 A; A=249-545.
DR   PDB; 3FY0; X-ray; 2.35 A; A=249-545.
DR   PDBsum; 1F3M; -.
DR   PDBsum; 1YHV; -.
DR   PDBsum; 1YHW; -.
DR   PDBsum; 1ZSG; -.
DR   PDBsum; 2HY8; -.
DR   PDBsum; 2QME; -.
DR   PDBsum; 3DVP; -.
DR   PDBsum; 3FXZ; -.
DR   PDBsum; 3FY0; -.
DR   ProteinModelPortal; Q13153; -.
DR   DIP; DIP-31016N; -.
DR   IntAct; Q13153; 24.
DR   MINT; MINT-92897; -.
DR   STRING; Q13153; -.
DR   PhosphoSite; Q13153; -.
DR   PRIDE; Q13153; -.
DR   Ensembl; ENST00000356341; ENSP00000348696; ENSG00000149269.
DR   GeneID; 5058; -.
DR   KEGG; hsa:5058; -.
DR   UCSC; uc001oyg.2; human.
DR   UCSC; uc001oyh.2; human.
DR   CTD; 5058; -.
DR   GeneCards; GC11M077033; -.
DR   H-InvDB; HIX0009965; -.
DR   HGNC; HGNC:8590; PAK1.
DR   HPA; CAB005312; -.
DR   HPA; HPA003565; -.
DR   MIM; 602590; gene.
DR   PharmGKB; PA32917; -.
DR   eggNOG; prNOG16871; -.
DR   HOVERGEN; HBG108518; -.
DR   OMA; EATKNNH; -.
DR   OrthoDB; EOG9N8TQ5; -.
DR   PhylomeDB; Q13153; -.
DR   BRENDA; 2.7.11.1; 247.
DR   Pathway_Interaction_DB; angiopoietinreceptor_pathway; Angiopoietin receptor Tie2-mediated signaling.
DR   Pathway_Interaction_DB; aurora_a_pathway; Aurora A signaling.
DR   Pathway_Interaction_DB; epha2_fwdpathway; EPHA2 forward signaling.
DR   Pathway_Interaction_DB; ephbfwdpathway; EPHB forward signaling.
DR   Pathway_Interaction_DB; p38alphabetapathway; Regulation of p38-alpha and p38-beta.
DR   Pathway_Interaction_DB; s1p_s1p2_pathway; S1P2 pathway.
DR   Pathway_Interaction_DB; met_pathway; Signaling events activated by Hepatocyte Growth Factor Receptor (c-Met).
DR   Pathway_Interaction_DB; vegfr1_2_pathway; Signaling events mediated by VEGFR1 and VEGFR2.
DR   Reactome; REACT_18266; Axon guidance.
DR   Reactome; REACT_6900; Signaling in Immune system.
DR   NextBio; 19488; -.
DR   ArrayExpress; Q13153; -.
DR   Bgee; Q13153; -.
DR   CleanEx; HS_PAK1; -.
DR   Genevestigator; Q13153; -.
DR   GermOnline; ENSG00000149269; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005925; C:focal adhesion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005518; F:collagen binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:HGNC.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0007010; P:cytoskeleton organization; TAS:HGNC.
DR   GO; GO:0006984; P:ER-nucleus signaling pathway; TAS:HGNC.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein amino acid autophosphorylation; IDA:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000095; PAK_box_Rho-bd.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR015750; Ser/Thr_kinase_Pak-rel.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   PANTHER; PTHR22986:SF84; Pak_like; 1.
DR   Pfam; PF00786; PBD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00285; PBD; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Allosteric enzyme; Alternative splicing;
KW   Apoptosis; ATP-binding; Cell junction; Complete proteome; Cytoplasm;
KW   Kinase; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    545       Serine/threonine-protein kinase PAK 1.
FT                                /FTId=PRO_0000086460.
FT   DOMAIN       75     88       CRIB.
FT   DOMAIN      270    521       Protein kinase.
FT   NP_BIND     276    284       ATP (By similarity).
FT   REGION       70    140       Autoregulatory region.
FT   REGION       75    105       GTPase-binding (By similarity).
FT   REGION      132    270       Interaction with CRIPAK.
FT   ACT_SITE    389    389       Proton acceptor.
FT   BINDING     299    299       ATP (By similarity).
FT   MOD_RES      21     21       Phosphoserine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES      57     57       Phosphoserine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES      84     84       Phosphothreonine; by OXSR1 (By
FT                                similarity).
FT   MOD_RES     144    144       Phosphoserine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     149    149       Phosphoserine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     199    199       Phosphoserine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     204    204       Phosphoserine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     212    212       Phosphothreonine.
FT   MOD_RES     219    219       Phosphothreonine.
FT   MOD_RES     220    220       Phosphoserine.
FT   MOD_RES     223    223       Phosphoserine (By similarity).
FT   MOD_RES     225    225       Phosphothreonine.
FT   MOD_RES     229    229       Phosphothreonine.
FT   MOD_RES     230    230       Phosphothreonine.
FT   MOD_RES     256    256       N6-acetyllysine.
FT   MOD_RES     423    423       Phosphothreonine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     474    474       Phosphotyrosine.
FT   VAR_SEQ     518    545       HQFLKIAKPLSSLTPLIAAAKEATKNNH -> VRKLRFQVF
FT                                SNFSMIAASIPEDCQAPLQPHSTDCCS (in isoform
FT                                2).
FT                                /FTId=VSP_017507.
FT   VARIANT     515    515       L -> V (in dbSNP:rs35345144).
FT                                /FTId=VAR_051654.
FT   MUTAGEN      83     83       H->L: Decreases activity; when associated
FT                                with L-86.
FT   MUTAGEN      86     86       H->L: Decreases activity; when associated
FT                                with L-83.
FT   MUTAGEN     107    107       L->F: Constitutively active.
FT   MUTAGEN     423    423       T->A: Decreases CDC42-stimulated activity
FT                                and autophosphorylation.
FT   CONFLICT     26     26       A -> V (in Ref. 2; AAA65441 and 3;
FT                                AAC24716).
FT   CONFLICT    237    237       R -> L (in Ref. 1; AAC50590).
FT   CONFLICT    379    379       F -> S (in Ref. 1; AAC50590).
FT   CONFLICT    503    503       E -> D (in Ref. 2; AAA65441).
FT   STRAND       80     90
FT   TURN         91     94
FT   STRAND       95     98
FT   HELIX       101    108
FT   HELIX       114    119
FT   HELIX       121    135
FT   STRAND      195    198
FT   HELIX       252    257
FT   TURN        258    260
FT   HELIX       266    269
FT   STRAND      275    279
FT   STRAND      282    289
FT   TURN        290    292
FT   STRAND      295    300
FT   HELIX       309    319
FT   STRAND      330    334
FT   STRAND      341    345
FT   STRAND      349    351
FT   HELIX       352    358
FT   HELIX       363    382
FT   HELIX       392    394
FT   STRAND      395    397
FT   STRAND      403    405
FT   STRAND      408    410
FT   HELIX       433    436
FT   HELIX       444    459
FT   TURN        463    466
FT   HELIX       469    478
FT   HELIX       487    489
FT   HELIX       492    501
FT   TURN        506    508
FT   HELIX       512    515
FT   HELIX       519    523
FT   HELIX       527    529
FT   HELIX       531    539
SQ   SEQUENCE   545 AA;  60647 MW;  1A95CD5F2195CD7B CRC64;
     MSNNGLDIQD KPPAPPMRNT STMIGAGSKD AGTLNHGSKP LPPNPEEKKK KDRFYRSILP
     GDKTNKKKEK ERPEISLPSD FEHTIHVGFD AVTGEFTGMP EQWARLLQTS NITKSEQKKN
     PQAVLDVLEF YNSKKTSNSQ KYMSFTDKSA EDYNSSNALN VKAVSETPAV PPVSEDEDDD
     DDDATPPPVI APRPEHTKSV YTRSVIEPLP VTPTRDVATS PISPTENNTT PPDALTRNTE
     KQKKKPKMSD EEILEKLRSI VSVGDPKKKY TRFEKIGQGA SGTVYTAMDV ATGQEVAIKQ
     MNLQQQPKKE LIINEILVMR ENKNPNIVNY LDSYLVGDEL WVVMEYLAGG SLTDVVTETC
     MDEGQIAAVC RECLQALEFL HSNQVIHRDI KSDNILLGMD GSVKLTDFGF CAQITPEQSK
     RSTMVGTPYW MAPEVVTRKA YGPKVDIWSL GIMAIEMIEG EPPYLNENPL RALYLIATNG
     TPELQNPEKL SAIFRDFLNR CLEMDVEKRG SAKELLQHQF LKIAKPLSSL TPLIAAAKEA
     TKNNH
//
